+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 15 Actively Recruiting clinical trials

E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety, tolerability, and immune response of the rVSV94G-LASV-GPC vaccine in adults and children living in West Africa. This Phase 2 clinical trial builds on earlier studies that showed the vaccine to be safe and able to protect animals against Lassa Fever. The study includes healthy adults, HIV-infected adults, adolescents, and children to better understand the vaccines effects across these groups and prepare for future effectiveness trials. Participants will receive one of three different doses of the rVSV94G-LASV-GPC vaccine or a placebo in a randomized, double-blinded manner. The vaccine is given as a single dose on Day 1. The study includes separate cohorts for healthy adults aged 18-70, HIV-infected adults aged 18-50, adolescents aged 12-17, and children aged 6-11. The study will observe vaccine safety and immune responses over various time points up to 7 months and beyond in some cases. During the study, participants will undergo medical exams, HIV testing, and monitoring for vaccine-related side effects. Researchers will measure antibody responses, vaccine presence in blood and body fluids, and immune system characteristics. Participants will be followed for safety and the duration of immune responses for up to 30 months in some cases. The study aims to provide detailed information on how well the vaccine is tolerated and how it stimulates the immune system in different age and health groups.

Age: 6Years - 70YearsAll GendersPhase 2
3 locations
L

Actively Recruiting

Researchers are evaluating etavopivat, a new oral medicine being developed for blood disorders such as sickle cell disease and thalassaemia. These inherited conditions affect hemoglobin, the protein responsible for carrying oxygen in the body. This long-term study aims to assess the safety and effectiveness of etavopivat treatment over a period of up to 264 weeks, or until the drug is approved in the participants country. Participants will receive one of several oral doses of etavopivat, with dosing adjusted by age those 12 years and older will receive Etavopivat A or C, while children younger than 12 years will receive Etavopivat B. The study involves multiple groups including adults, adolescents, and children with different types of sickle cell disease or thalassaemia. All participants have completed a prior etavopivat treatment study and are continuing treatment in this rollover study. During the study, participants will be regularly monitored for treatment-related side effects and clinical benefits. Researchers will track adverse events, blood crisis rates, hemoglobin levels, hospitalizations, and blood transfusion needs. The study includes long-term safety and efficacy assessments conducted over several years, with monitoring continuing until study completion or drug approval. Participants health and treatment responses will be carefully followed throughout this extended period.

Age: 2Years +All GendersPhase 3
107 locations
E

Actively Recruiting

Researchers are evaluating a urine test called the 3-metabolite biosensor to detect colorectal cancer CRC and precancerous polyps in adults living in Ghana, Tanzania, and South Africa. The study focuses on participants who either have symptoms of colorectal cancer, are undergoing screening colonoscopy, or have had recent colonoscopy or pathology results related to CRC or polyps. Participants will be observed using the 3-metabolite biosensor, which is designed to identify colorectal cancer and precancerous polyps from urine samples. The study includes individuals with various colonoscopy findings, including those with diagnosed CRC, adenomatous polyps, or no malignancy, and those presenting symptoms such as rectal bleeding. During the study, participants will provide urine samples for testing with the biosensor. Researchers will measure the sensitivity of the biosensor in detecting colorectal cancer and precancerous polyps over up to one year. Participants are asked to be willing to participate and meet the age criteria of 18 years or older. The study is observational and does not involve treatment interventions.

Age: 18Years +All Genders
4 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are studying changes in blood pressure and early signs of heart disease risk among pregnant women in their third trimester through six months after giving birth in Accra, Ghana. This study includes women aged 18 to 45 years, with or without pregnancy-related heart and metabolic complications. The goal is to find out if a postpartum education program can improve monitoring of cardiovascular risk and help develop better screening and intervention strategies to reduce long-term heart disease risk for women. Participants are randomly assigned to one of two groups. One group receives a structured cardiovascular risk-reduction program that includes home blood pressure monitoring and weekly education sessions about heart health, nutrition, physical activity, stress management, sleep, weight management, medication adherence, and long-term cardiovascular health after pregnancy. The other group receives enhanced postpartum care, featuring home blood pressure monitoring and scheduled health check-ins focusing on postpartum recovery, infant care, mental health, nutrition, infection prevention, and family planning support. Throughout the study, participants are monitored at baseline, three months, and six months after birth. Assessments include measuring carotid-femoral pulse wave velocity, systolic and diastolic blood pressure, and various cardiometabolic and vascular biomarkers. The study tracks how these measures change over time and evaluates the impact of the education programs. The total study duration spans from late pregnancy through six months postpartum, supporting ongoing health monitoring and education.

Age: 18Years - 45YearsFEMALEPhase Not Applicable
1 location
U

Actively Recruiting

Healthy Volunteer

This research aims to improve care for people with serious mental illness in West Africa, particularly those receiving treatment at traditional prayer camps. It evaluates a combined intervention involving a mobile health program and nurse-delivered pharmacotherapy. The study uses a stepped-wedge cluster randomized design to compare current care with the new intervention, focusing on psychiatric and depressive symptoms. The intervention includes a visiting nurse who provides medications directly to patients at the prayer camps. Additionally, camp staff receive training through a smartphone app called M-Healer, which supports delivery of psychosocial treatments, monitors patient health, and promotes human rights. Participants initially receive enhanced usual care, followed by gradual introduction of the full intervention across groups. Participants will be assessed at the start, mid-point 4 weeks, and end 8 weeks of the study to track changes in psychiatric and depressive symptoms. Data collection and monitoring will help evaluate the interventions impact. The total study duration extends until May 2027, allowing thorough observation and follow-up during and after the intervention periods.

Age: 18Years +All GendersPhase Not Applicable
1 location
G

Actively Recruiting

Researchers are actively monitoring the side effects of COVID-19 vaccines worldwide in healthcare workers, adults over 65, and schoolteachers. The study aims to estimate how common local and systemic side effects are for each vaccine brand, identify demographic and medical factors influencing side effects, and evaluate long-term consequences. It also compares the relative safety of different COVID-19 vaccines and examines how palliative drugs affect short-term side effect resolution. The project has two phases a cross-sectional survey and a prospective cohort study. Phase A uses an online questionnaire to collect information about short-term side effects occurring within 30 days after vaccination, covering either the first or second dose. Phase B follows volunteers interested in reporting long-term side effects and vaccine effectiveness after booster doses over five years, starting in 2022. Multiple COVID-19 vaccines are included, such as Pfizer-BioNTech, Moderna, AstraZeneca, Sinovac, Sinopharm, Sputnik V, Janssen, CureVac, Novavax, and Covaxin. Participants provide self-reported data through validated online questionnaires about side effect onset, duration, and intensity. The study tracks local and systemic side effects within 30 days post-vaccination as primary outcomes, with unrecognized side effects as secondary outcomes. Volunteers are followed for long-term safety and vaccine effectiveness, with a total observation period extending up to five years. This ongoing monitoring helps researchers understand vaccine safety profiles and side effect patterns in different populations.

Age: 18Years +All Genders
14 locations
G

Actively Recruiting

Healthy Volunteer

Researchers are investigating the genetic basis of Type 2 Diabetes T2D and related conditions among the Yoruba people in Ibadan, Nigeria, as part of a broader effort to understand how genetic and lifestyle factors contribute to T2D and its complications. This observational study aims to identify genetic variants linked to diabetes risk and to explore whether variants found in European populations also affect West Africans. The study also seeks to develop a large-scale genetic resource for future research and to describe cardiometabolic traits in diverse African populations. Participants include 300 unrelated cases of T2D and 300 matched controls without diabetes from the Yoruba ethnic group. Both newly diagnosed and treated T2D patients are enrolled. The study involves collecting blood and urine samples, measuring blood pressure and body composition, conducting eye exams, and administering questionnaires. Genetic analyses, including a genome-wide association study GWAS and resequencing of candidate genes, will be performed using samples processed in Nigeria and at the National Institutes of Health. During participation, individuals will undergo several assessments such as finger prick blood glucose tests, confirmatory fasting glucose tests when needed, and anthropometric measurements. Researchers will also perform eye examinations and gather detailed health information through questionnaires. The study will monitor a range of outcomes including T2D presence, hypertension, obesity, metabolic syndrome, and related kidney and lipid conditions. Participation involves initial testing and sample collection, with DNA analysis and genetic studies conducted subsequently, supporting ongoing research in diabetes genetics.

Age: 18Years - 120YearsAll Genders
5 locations
U

Actively Recruiting

This research aims to improve vital signs monitoring in children with trauma or postoperative appendicitis in hospitals in Ghana, where manual vital signs checks are common due to non-functional continuous bedside monitors. The study evaluates a continuous patient monitoring system using the Garmin Venu 3, a consumer wearable device that tracks heart rate, oxygen saturation, and respiratory rate, to identify early signs of physiological deterioration. Participants will use the CONSOL platform, which collects and displays vital signs data in near real-time via a tablet or smartphone. This system is tested in pediatric trauma patients in the Emergency Department and pediatric patients recovering from appendectomy in surgical units. The device provides snapshots of vital signs over the past minute, hour, and day to assist monitoring. During the study, participants vital signs will be monitored using the wearable device, and changes will be compared to pre-implementation values. Researchers will collect data on heart rate, respiratory rate, and oxygen saturation, focusing on how quickly abnormal readings are detected. The study runs from screening through intervention and monitoring up to the study completion date, with ongoing evaluation of the monitoring systems impact on care.

Age: 3Years - 18YearsAll GendersPhase Not Applicable
1 location
F

Actively Recruiting

Researchers are studying the impact of starting a multidisciplinary obstetrics care program for pregnant women with sickle cell disease SCD in a non-academic hospital in Ghana. The study aims to see if this approach can reduce maternal deaths by 50% compared to before the program began. This is important because SCD significantly increases the risk of death during pregnancy, especially in low-resource settings like Ghana, where such care programs are limited to academic hospitals. The program adapts successful care protocols from an academic hospitals multidisciplinary SCD obstetrics team, including obstetricians, general physicians, anesthesiologists, and nurses. Pregnant women with SCD attending the non-academic hospital will receive care following these protocols. The study uses a before-and-after design to compare mortality rates, with a focus on task-shifting responsibilities to existing hospital staff to improve reach and sustainability. Participants will be pregnant women with confirmed SCD up to 34 weeks gestation, aged 18 to 45, attending the non-academic hospital. The study will monitor maternal mortality up to 40 weeks for each participant. Researchers will collect medical data, conduct interviews, and track outcomes to evaluate the programs feasibility and effectiveness. The study plans to recruit 198 participants over three years, with ongoing assessments to understand barriers and support needed for successful implementation.

Age: 18Years - 45YearsFEMALEPhase Not Applicable
1 location
R

Actively Recruiting

Researchers are conducting a randomized control trial to evaluate the Jada4 System, a novel vacuum-induced device designed to treat postpartum hemorrhage PPH, a leading cause of maternal death worldwide, especially in low and middle income countries. The study aims to compare the effectiveness, safety, and cost-effectiveness of this device against standard care in women experiencing PPH, defined as significant blood loss or symptoms of hypovolemia after childbirth. PPH commonly results from uterine atony, where the uterus does not contract properly after delivery. The trial includes two groups one group will receive the Jada4 System when initial medical treatments fail and blood loss reaches 1000 mL this device uses low-level vacuum pressure to help the uterus contract and control bleeding rapidly. The other group will receive standard care which may include additional medications, tranexamic acid, condom catheter balloon tamponade, or surgical interventions if bleeding continues. The device remains in place for at least one hour during treatment, followed by monitoring before removal. Participants are enrolled at two hospitals in Ghana, a country with a high burden of PPH. Participants will be monitored from delivery until six weeks postpartum. Researchers will assess maternal survival without needing surgery, time to control bleeding, hemoglobin levels, blood transfusion rates, surgical procedures, maternal death rates, additional medication use, patient satisfaction, and any adverse events related to the device. The study also evaluates quality of life and cost-effectiveness. Safety and treatment outcomes will be closely followed during this period to determine the devices potential benefits compared to standard care.

Age: 18Years - 44YearsFEMALEPhase Not Applicable
2 locations

1-10 of 15

1